A single class of drug has the potential to treat infectious diseases, zoonotic diseases, autoimmune diseases, and even cancer. Messenger ribonucleic acid (mRNA) drugs made headlines during the height of the COVID-19 pandemic, when mRNA-based vaccines set the world back on its axis. Now, the field had shifted beyond pandemic response and toward increasingly ambitious disease targets, and mRNA drugs and vaccines remain perhaps the most promising priority in vaccine development.
A review published via Cureus Journal of Medical Science focuses on the ongoing clinical exploration of mRNA-based treatments and their transformative potential in modern medicine. Read on to learn more.
Innovation in mRNA Vaccines: How Do They Work?
Though mRNA vaccines took the world stage in the early 2020s during the height of the COVID-19 pandemic, DNA- and mRNA-based gene vaccines truly gained prominence in the 1990s. Experts realized that these drugs had the potential to “instruct” the body to repair itself, making mRNA a promising target for difficult-to-treat conditions.
mRNA therapeutics rely on messenger ribonucleic acid (mRNA), a genetic molecule that carries instructions for creating essential target proteins, which allow the body to heal and grow. When a protein is needed, a section of DNA is copied into an mRNA strand. The mRNA then leaves the cell’s nucleus and enters the cytoplasm, where ribosomes “read” the mRNA instructions and build the protein, brick by brick.
The mechanism behind mRNA vaccines involves tapping into a synthetic mRNA sequence. The synthetic sequence encodes a viral antigen that triggers cells to produce an immune response. Certain conditions, including cancer and autoimmune diseases, call for highly specific vaccines; fortunately, these synthetic sequences enable mRNA vaccines to target specific foes.
mRNA Vaccines for Cancer Treatment
The mRNA used in the Pfizer-BioNTech and Moderna COVID-19 vaccines encodes the spike protein of SARS-CoV-2, which the immune system can then recognize as a foreign antigen. However, where infectious disease mRNA vaccines target specific proteins, cancer vaccines must target tumor-specific antigens based on the highly individual mutations present in a certain tumor.
Personalized cancer mRNA vaccines are currently being studied to treat melanoma, lung cancer, and colorectal cancer, all of which require personalized treatment strategies to reduce potentially negative impacts on the subject’s body. However, several obstacles exist, including the vast diversity of tumor characteristics and the traditionally immunosuppressive tumor microenvironment.
Despite these challenges, the research has shown promise. For example, the Phase I trial of BNT111, an mRNA cancer vaccine, demonstrated a strong immune response in patients with advanced melanoma.
mRNA Vaccines and Zoonotic Diseases: Ebola, Hantavirus, and More
mRNA vaccines have a unique feature that makes them compelling candidates for zoonotic diseases such as Hantavirus and Ebola, which can spread from animals to humans. These vaccines have the potential to provide an unusually rapid response to emerging infectious diseases. While significant further research is needed, an overview of Hantavirus treatment options shows that mRNA is an exciting new option to explore. This may be especially relevant as a new wave of Ebola, a zoonotic disease, devastates parts of West Africa.
Drug Development Perspectives
The examples listed above represent only a small percentage of ongoing mRNA research. These vaccines and drug therapies have also been tested in genetic conditions and autoimmune disorders, specifically for multiple sclerosis and rheumatoid arthritis.
As mentioned above, mRNA vaccines and therapeutics offer a tantalizing combination of speed and personalization. mRNA vaccines are fast, yes; we know that from the swift development of life-saving mRNA vaccines during the height of the COVID-19 pandemic. But how can manufacturers address, for example, cold-chain storage needs? How can these drugs scale? How can they be approved on an efficient timeline? Clinical strategy, immunogenicity testing, safety monitoring, and regulatory readiness are all significant factors that must shape the future of mRNA vaccine development.
_____
As experts leverage important lessons learned, the future of mRNA vaccine innovation has never looked brighter. However, success will depend on rigorous science, operational precision, and regulatory-quality evidence derived from strong clinical research programs and partners.
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.